권호기사보기
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
대표형(전거형, Authority) | 생물정보 | 이형(異形, Variant) | 소속 | 직위 | 직업 | 활동분야 | 주기 | 서지 | |
---|---|---|---|---|---|---|---|---|---|
연구/단체명을 입력해주세요. |
|
|
|
|
|
* 주제를 선택하시면 검색 상세로 이동합니다.
Objectives: To conduct a cost-minimization analysis (CMA) of nuclear scintigraphy (NS) compared to endomyocardial biopsy (EMB) for transthyretin amyloid cardiomyopathy (ATTR-CM) diagnosis in Korea. Methods: CMA was performed using a decision tree model. The target populations were patients with suspected ATTR-CM. After screening of the entire target populations to rule out amyloid light-chain amyloidosis, patients were assigned to either NS followed by EMB as needed (NS group) or EMB without an NS as a gatekeeper (EMB group). We assumed that 12% of the NS group would not meet the diagnostic criteria of ATTR-CM and that these patients would still receive EMB after the NS. We calculated the costs from the healthcare system perspective using the micro-costing approach. One-way sensitivity analysis was conducted. Results: The overall cost was estimated at 717,714 KRW per patient in the NS group and 1,425,772 KRW per patient in the EMB group. Consequently, the NS group cost 708,058 KRW less than the EMB group. The sensitivity analysis result showed that the higher the proportion of patients undergoing EMB after the NS, the lower the cost reduction effect. Conclusion: Compared to direct EMB for ATTR-CM diagnosis, selective EMB after NS reduces the overall costs in Korea.
*표시는 필수 입력사항입니다.
*전화번호 | ※ '-' 없이 휴대폰번호를 입력하세요 |
---|
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
번호 | 발행일자 | 권호명 | 제본정보 | 자료실 | 원문 | 신청 페이지 |
---|
도서위치안내: 정기간행물실(524호) / 서가번호: 국내05
2021년 이전 정기간행물은 온라인 신청(원문 구축 자료는 원문 이용)
우편복사 목록담기를 완료하였습니다.
*표시는 필수 입력사항입니다.
저장 되었습니다.